SynthesisClinical cardiology2018
Advanced chronic kidney disease: Relationship to outcomes post-TAVR, a meta-analysis.
Synthesis in Clinical cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Advanced chronic kidney disease: Relationship to outcomes post-TAVR, a meta-analysis.Clinical cardiology · 2018Pooled it
- TAVR vs. SAVR in Patients With Severe Aortic Stenosis and Chronic Kidney Disease Undergoing Dialysis: A Comprehensive Meta-Analysis.Cardiology research and practice · 2026Article
- Transcatheter Aortic Valve Replacement in Special Population Groups.Reviews in cardiovascular medicine · 2025Review
- Chronic kidney disease and valvular heart disease: State of the art.Physiological reports · 2025Review
- Prognostic value of N-Acetylglucosaminidase and Kidney-injury-molecule-1 in TAVI patients with severe aortic stenosis.Biomarkers in medicine · 2024Article
- A Novel Protocol for Contrast-Free Transcatheter Aortic Valve Replacement Evaluation and Implantation.Journal of the Society for Cardiovascular Angiography & Interventions · 2024Article
- In-hospital outcomes of transcatheter aortic valve replacement in patients with chronic and end-stage renal disease: a nationwide database study.BMC cardiovascular disorders · 2024Article
- Article
- The impact of transcatheter aortic valve implantation planning and procedure on acute and chronic renal failure.Cardiology journal · 2023Article
- Valvular Heart Disease in Patients with Chronic Kidney Disease.European cardiology · 2022Review
- Futility in Transcatheter Aortic Valve Implantation: A Search for Clarity.Interventional cardiology (London, England) · 2022Review
- Review
- Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options.Circulation · 2021Article
- Improvement of renal function after transcatheter aortic valve replacement and its impact on survival.BMC nephrology · 2021Article
- [Valvular heart disease in patients with chronic kidney disease].Der Internist · 2020Review
- Acute kidney injury after transcatheter aortic valve replacement in the elderly: outcomes and risk management.Clinical interventions in aging · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is associated with worse outcomes in high-surgical-risk patients undergoing transcatheter aortic valve replacement (TAVR). However, it is unclear whether this relationship is apparent in lower-surgical-risk patients. We sought to analyze existing literature to assess whether or not advanced CKD is associated with increased mortality or a greater incidence of adverse events (specifically major stroke, bleeding, and vascular complications). We searched PubMed and Embase (2008-2017) for relevant studies. Studies with <1 year follow-up and those not evaluating advanced CKD or outcomes post-TAVR were excluded. Our co-primary endpoints were the incidence of short-term mortality (defined as in-hospital or 30-day mortality) and long-term mortality (1 year). Our secondary endpoints included incidence of major stroke, life-threatening bleeding, and major vascular complications. Eleven observational studies with a total population of 10709 patients met the selection criteria. Among patients with CKD there was an increased risk of short- and long-term mortality in high-surgical-risk patients who underwent TAVR (hazard ratio [HR]: 1.51, 95% confidence interval [CI]: 1.22-1.88 and HR: 1.56, 95% CI: 1.38-1.77, respectively; P < 0.01). However, there was no association between CKD and mortality in low- to intermediate-risk patients (HR: 1.35, 95% CI: 0.98-1.84, P = 0.06 in short-term and HR: 1.08, 95% CI: 0.92-1.27, P = 0.34 in long-term). In low- to intermediate-risk TAVR patients, advanced CKD is not associated with increased mortality or poorer safety outcomes. These findings should be factored into the clinical decision-making process regarding TAVR candidacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.